drugset / Trial / NCT01723254

A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis

NCT01723254 ↗

Phase 1 Completed 190 enrolled Pfizer
RandomizedQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of different doses of PF-06444753 and PF-06444752 in subjects with allergic rhinitis.

Timeline

Start
2012-12
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IGE-1 Vaccine — Intramuscular
Subject IGE-2 Vaccine — Intramuscular

Indications